Bayer's Legal and Financial Crossroads: A Pivotal Fortnight Ahead

Bayer faces a pivotal Supreme Court hearing on glyphosate litigation, its AGM, and a major cash flow crunch in late April and May 2026, testing its resilience.

The coming weeks will test Bayer's resilience like few periods before. Between late April and mid-May, the German life sciences giant faces a convergence of critical events that could reshape its financial and legal landscape for years to come. At the heart of the matter lies the enduring legacy of the 2018 Monsanto acquisition, which has already cost the company over $11 billion in settlements and judgments.

All eyes are first on Washington D.C. Oral arguments before the US Supreme Court in the case of Durnell v. Monsanto are scheduled for April 27, 2026. The outcome could fundamentally alter the trajectory of the long-running glyphosate litigation. Bayer’s central argument is that the federal FIFRA law preempts state-level requirements for cancer warning labels on products like Roundup. A favorable ruling would undermine the legal basis for thousands of future claims. The Trump administration’s support for Bayer’s position marks a significant shift from the previous Biden-era stance.

However, the path is not clear. Opposition has mounted, with attorneys general from Texas, Florida, and Ohio filing amicus briefs against Bayer’s preemption argument. In total, 18 such briefs have been submitted. A final decision from the Supreme Court is expected by the end of June. In a parallel development, a Missouri judge has given preliminary approval to a $7.25 billion class action settlement on the state level. Furthermore, Kentucky recently became the third US state to pass a law shielding Bayer from certain types of glyphosate lawsuits.

Just days before the Supreme Court hearing, Bayer’s shareholders will convene. The company’s virtual Annual General Meeting on April 24 is set to approve a proposed dividend of 0.11 euros per share, unchanged from the previous year. This commitment to shareholder returns is notable given the severe pressure on the company’s cash position. For 2026, the free cash flow is projected to be deeply negative, potentially reaching -2.5 billion euros, largely due to massive legal costs. In 2025, free cash flow had already declined by 32.9% to 2.1 billion euros.

The AGM will also oversee a leadership transition on the Supervisory Board, with Marcel Smits and Alfred Stern slated to replace Paul Achleitner and Colleen Goggins. The dividend will go ex on April 27, with payment following on April 29.

Despite the legal overhang and new US import tariffs on pharmaceuticals, Bayer’s management maintains its financial guidance for 2026. Chief Operating Officer Sebastian Guth stated the tariffs, capped at 15% under an EU trade agreement, do not jeopardize annual targets. The company continues to forecast revenue between 45 and 47 billion euros, with an EBITDA target of 9.6 to 10.1 billion euros, figures it says already account for the tariff impact.

The sequence of events concludes on May 12 with the release of the first-quarter results. This report will serve as the management’s first official commentary following the Supreme Court hearings, offering a crucial gauge of their internal assessment of the legal battle. Operationally, the focus will be on the pharmaceutical division’s new hope, drugs Nubeqa and Kerendia, and their ability to offset revenue gaps from expiring patents.

On the stock market, Bayer’s shares have gained 5.51% since the start of the year, closing Friday at 40.12 euros. While the stock trades about 18% below its 52-week high, it has doubled in value over the past twelve months. The company’s net financial debt stood at 29.8 billion euros at the end of 2025. The next four weeks will determine whether recent gains are the foundation for a sustained recovery or merely a pause in a longer struggle.